On December 16 – 18, 2019 the Secretariat of the Global AMR R&D Hub was presented at the 3rd International Symposium on Alternatives to Antibiotics (ATA2019, https://www.ars.usda.gov/alternativestoantibiotics/) in Bangkok, where alternative strategies to prevent and control animal diseases were discussed.
Dr Ralf Sudbrak, Scientific Programme Officer at the Hub, presented the progress about the “Developing a global dynamic dashboard as a one-stop shop for AMR related research and development in One Health Sectors”.
The Secretariat of the Global AMR R&D Hub had the pleasure of delivering one of the key note presentations at the Emerging Antimicrobials and Diagnostics in AMR 2019 symposium organised by AMR Insights in Amsterdam on November 19 and 20, 2019. The presentation held by Dr Jennie Hood, Scientific Programme Officer at the Hub, focused on the ambitions of the Global AMR R&D Hub’s Dynamic Dashboard and the results of the recent public consultation on the draft Collaboration Framework. A copy of the presentation is available here.
The Global AMR R&D Hub’s Board of Members met in Paris on October 31, 2019. The meeting was hosted by the French ministry of higher education, research and innovation. India has joined the Hub in September as the newest Member and the Food and Agriculture Organisation of the United Nations (FAO) has joined the Hub as an Observer. The representatives attended a face-to-face Board meeting of the Hub for the first time and were extended a special welcome. Expanding the membership of the Hub’s Board of Members is a standing agenda item and countries and non-governmental donor organisations interested in joining the Board will find the relevant information on how to join here.
The current activities of the Global AMR R&D Hub for developing the Dynamic Dashboard and launching it in Q1 2020 were discussed. The Expert Advisory Group for determining the market potential of interventions addressing AMR reported on their work. Professor Towse from the Office of Health Economics gave a presentation about the study “HTA and Payment Mechanisms for New Drugs to Tackle AMR” that was commissioned by Wellcome Trust.
On 30 October the Board had its first joint meeting with the Stakeholder Group of the Global AMR R&D Hub. The Stakeholder Group gave input to the work of the Hub and the evaluation framework was presented by the external contractor who has been recruited for this task.
On October 27, 2019 the Global AMR R&D Hub convened currently active groups undertaking work modelling the development process for antibiotics. This small technical roundtable discussion was held in Berlin and facilitated a valuable exchange between expertise globally. The opportunity to better understand each other’s work, compare notes and discuss shared challenges was valuable as both these groups, and the Global AMR R&D Hub, progress with their work in understanding development realities and resource constraints in this field.
On October 27, 2019 the Secretariat Lead of the Global AMR R&D Hub Dr Elmar Nimmesgern participated in a panel discussion ‘Antimicrobial Resistance’ at the World Health Summit. www.worldhealthsummit.org
The direct link to the session is:
The AMR theme has been addressed by several other sessions at the World Health Summit, highlighting the importance of tackling this issue.
With India joining, the global partnership working to address challenges and improve coordination and collaboration in AMR R&D is expanded. Membership now consists of 16 countries, the European Commission, 2 philanthropic foundations and 4 international organisations (as observers).
On September 16-17, 2019 the Secretariat of the Global AMR R&D Hub was represented at the Stakeholder Forum of the EU Joint Action Antimicrobial Resistance and Healthcare-Associated Infections (EU JAMRAI) in Rome: https://eu-jamrai.eu/eu-jamrai-second-annual-meeting/
The Secretariat Lead, Dr Elmar Nimmesgern, participated in the round-table discussion on Economic models for stimulating innovation and access to antimicrobials. In the discussion he highlighted the importance of framing the discussion on incentives for antibiotics, both new and old, with concrete examples.
Dr Nimmesgern also led a workshop discussion on the antibiotics debate in Germany at the MSD Health Forum 2019 in Munich. There he suggested that discussions in Germany on assuring availability of innovative antibiotics and incentives for R&D may be relevant for other countries and there would be benefit in considering how the German approaches could be put into an international context and communicated more transparently.